BOULDER, Colo.--(BUSINESS WIRE)--Array BioPharma Inc. (NASDAQ: ARRY) today announced that it has commenced dosing ARRY-797, a novel, small molecule p38 inhibitor, in a Phase 2 clinical trial to evaluate the efficacy of this drug for treating pain in dental patients undergoing third molar extraction.
“I am delighted that we are now dosing patients in our Phase 2 study to evaluate the efficacy of ARRY-797 in the management of postoperative dental pain,” said John Yates, MB ChB, MD, Chief Medical Officer, Array BioPharma. “We believe we are likely to see significant efficacy in acute pain based upon ARRY-797’s pharmacodynamic activities to date. This model has been a good predictor of acute analgesic effects of various pain medications.”
